Discover and read the best of Twitter Threads about #LNPs
Most recents (3)
Ironic
Dr Burkhardt's team published more autopsy data on COVID 💉 patients confirming lymphocytes in every organ; which means it's a good time to revisit this little gem of a paper, with many highly predictive statements about the LNPs in the
#WarpedSpeed 💉>
Dr Burkhardt's team published more autopsy data on COVID 💉 patients confirming lymphocytes in every organ; which means it's a good time to revisit this little gem of a paper, with many highly predictive statements about the LNPs in the
#WarpedSpeed 💉>
Before we start it's interesting to note the paper is from a team at Thomas Jefferson University.
The same 🏫 which forced their president to publicly apologize for liking @AlexBerenson's tweets questioning the safety and efficiency of the 💉s.
The same 🏫 which forced their president to publicly apologize for liking @AlexBerenson's tweets questioning the safety and efficiency of the 💉s.
The research looked at data showing the highly inflammatory nature of the lipid nanoparticles when tested in 🐁, injected into the muscle, and intranasally. >
ncbi.nlm.nih.gov/pmc/articles/P…
ncbi.nlm.nih.gov/pmc/articles/P…
26/50 The detected "SV40 promoter with 72bps indel" is a "nuclear localization signal" that means either the #plasmid or one of its expressed proteins can be transported into host cell nuclei,...
27/50 ...where the host DNA is found, creating an open question of whether host DNA interaction will occur and to what effect e.g. integration with human DNA. anandamide.substack.com/p/sequencing-o…
28/50 Potential effects of plasmid #contamination in vivo? Notable, five chemistry professors from German universities have been studying #Pfizer #BionTech's covid vaccine. They addressed some questions to the company. Where does the gray tone come from?
berliner-zeitung.de/gesundheit-oek…
berliner-zeitung.de/gesundheit-oek…
[Thread]
Two #ASGCT20 morning sessions focused on lung delivery. Cool work, but it seems to me that the big issues for clinical stage haven't really been addressed:
Two #ASGCT20 morning sessions focused on lung delivery. Cool work, but it seems to me that the big issues for clinical stage haven't really been addressed:
#AAV can target specific cell types in the lung, and multiple groups have rescued mouse models of genetic diseases. But both new and old lung-trophic capsids seem to hit T2 epithelial cells, which turn over and lose non-integrating transgenes.
Why does the virus end up in these cells? Are the T1 cells designed to reject microbes? What about fibroblasts and other cells, that do get transduced in some tissues?
